Patents Examined by Christine J. Saoud
  • Patent number: 11318186
    Abstract: The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the treatment of EPI or pancreatitis resulting from surgical procedures.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: May 3, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: David J. Mangelsdorf, Steven A. Kliewer, Katie C. Coate, Genaro Hernandez
  • Patent number: 11311605
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: April 26, 2022
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Patent number: 11312780
    Abstract: Antibodies directed against the endothelin receptor sub-type B, in particular monoclonal antibodies, a fragment or derivative thereof. The present disclosure also relates to the therapeutic, diagnostic use or as a research tool of such an antibody in the field of cancers and in particular glioblastoma.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: April 26, 2022
    Assignee: COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES
    Inventors: Didier Boquet, Frédéric Ducancel, Amaury Herbet, Narciso Costa, Jean-Philippe Hugnot
  • Patent number: 11307209
    Abstract: The present invention relates to an immunoassay method for placental growth factor 2 (PlGF-2) detection in pregnant subjects. Furthermore the invention relates to the use of said method for the diagnosis, prognosis, risk assessment and therapy control of prenatal disorders comprising the determination of the level of PlGF-2 in said pregnant subjects.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 19, 2022
    Assignee: CÉZANNE S.A.S.
    Inventors: Gaïané Demirdjian, Delphine Espinasse
  • Patent number: 11274142
    Abstract: The present invention provides a fusion protein containing TGF-? receptor and pharmaceutical use thereof. Further, the present invention provides a bifunctional fusion protein comprising the PD-L1 antibody targeting portion and the TGF-?RII extracellular domain, and a pharmaceutical composition comprising the fusion protein containing TGF-? receptor, and the use thereof in the preparation of anti-cancer drug.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: March 15, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jinming Gu, Xiao Luo, Weikang Tao
  • Patent number: 11253573
    Abstract: The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: February 22, 2022
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou
  • Patent number: 11253572
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: February 22, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: George Yancopoulos
  • Patent number: 11248052
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing ?-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: February 15, 2022
    Assignee: AMGEN INC.
    Inventors: Yang Li, Jennitte LeAnn Stevens, Chadwick Terence King, Ian Nevin Foltz, Gunasekaran Kannan, Junming Yie, Shaw-Fen Sylvia Hu
  • Patent number: 11246909
    Abstract: The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: February 15, 2022
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou
  • Patent number: 11248031
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 15, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski
  • Patent number: 11241481
    Abstract: Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: February 8, 2022
    Assignee: NGM BIOPHARMACEUTICALS, INC.
    Inventors: Lei Ling, Hui Tian
  • Patent number: 11235031
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 1, 2022
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Patent number: 11236171
    Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 1, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien, Haiying Qin
  • Patent number: 11230582
    Abstract: The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 25, 2022
    Assignee: SANOFI
    Inventors: Mark Sommerfeld, Thomas Langer, Oliver Boscheinen, Matthias Dreyer, Werner Dittrich, Paul Habermann
  • Patent number: 11224634
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: January 18, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Patent number: 11209444
    Abstract: The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularisation. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: December 28, 2021
    Assignees: VEGENICS PTY LIMITED, THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
    Inventors: Megan E. Baldwin, Kameran Lashkari, Jie Ma
  • Patent number: 11202822
    Abstract: The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: December 21, 2021
    Assignees: Ultragenyx Pharmaceutical Inc., Kyowa Kirin Co., Ltd.
    Inventors: Emil D. Kakkis, Javier San Martin, Tomohiro Sudo
  • Patent number: 11185570
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: November 30, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Patent number: 11179440
    Abstract: A fusion protein containing a biologically active protein and an FGF21 mutant protein, a pharmaceutical composition containing the fusion protein, and their uses are disclosed. The fusion protein and the pharmaceutical composition are effective in treating a liver disease including hepatitis, hepatic fibrosis, and hepatic cirrhosis. The fusion protein has effects of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: November 23, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Han Na Hong, Jun Hwan Kim, Hyun Ho Choi, Dohoon Kim, Taewang Kim, Se Woong Oh, Moo Young Song, Jong Gyun Kim
  • Patent number: 11179323
    Abstract: The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: November 23, 2021
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou